Abstract: Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
Type:
Application
Filed:
November 22, 2004
Publication date:
July 21, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
Abstract: Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
Type:
Application
Filed:
November 29, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
November 22, 2004
Publication date:
July 14, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
Type:
Application
Filed:
November 30, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
Type:
Application
Filed:
December 7, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan
Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Type:
Application
Filed:
November 10, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
Type:
Application
Filed:
November 22, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
Type:
Application
Filed:
November 29, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
Type:
Application
Filed:
November 10, 2004
Publication date:
July 7, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins, Dechi Guan